1.A Case of Wilson-Mikity Syndrome.
Jung Suk LEE ; Young Kyun LEE ; Hyang Suk YOON ; Yeon Kyun OH
Journal of the Korean Pediatric Society 1990;33(5):675-679
No abstract available.
2.The Influence of Hepatitis B Virus to Neonates.
Dong Hak SHIN ; Rac Kyun RO ; Sung Do YOON
Journal of the Korean Pediatric Society 1986;29(1):51-57
No abstract available.
Hepatitis B virus*
;
Hepatitis B*
;
Hepatitis*
;
Humans
;
Infant, Newborn*
3.A case of type 4 renal tubular acidosis resulting from captopril administration.
Jeong Eun PARK ; Gyu Bog CHOI ; Kyun Il YOON
Korean Journal of Nephrology 1991;10(4):620-624
No abstract available.
Acidosis, Renal Tubular*
;
Captopril*
4.Linear Basal Cell Nevus: Report of One Case.
Wook Hwa BARK ; Ho Kyun CHOI ; Bong Chan YOON
Korean Journal of Dermatology 1970;8(2):59-62
The author observed one case of typical Linear bassal cell nevus who was 3 year old girl. Since birth, skin lesions reveal a linear band like nodules along the left lateral margin of nose, which are consists of pinhead sized, normal skin colored, pearly and translucent papules. Histopathologically, the preparations showed muItifocal irregular masses of basal type epithelial cells in continuity at pilosebaceous follicles and the cells were oval or spindle shaped and a peripheral palisade arrangement. But comedones and nevus cells were not identified. Diagnosis confirmed by clinical appearance, histopathologically and other clinical study. There were marked improvement by the locaI application of 2% 5-Fluorouracil solution.
Child, Preschool
;
Diagnosis
;
Epithelial Cells
;
Female
;
Fluorouracil
;
Humans
;
Nevus*
;
Nose
;
Parturition
;
Skin
5.An experimental study on the effect of diphenylhydantoin and gaba on Na+, K=+ - atpase in microsomal fraction of rat brain.
Sa Jun CHUNG ; Kyun Kil YOON ; Chang Il AHN
Journal of the Korean Child Neurology Society 1993;1(1):33-40
No abstract available.
Adenosine Triphosphatases*
;
Animals
;
Brain*
;
gamma-Aminobutyric Acid*
;
Phenytoin*
;
Rats*
6.A clinical analysis of acute renal failure accompanying rhabodomyolysis.
Ji Soo LEE ; Gyu Bok CHOI ; Kyun Il YOON
Korean Journal of Nephrology 1993;12(4):609-615
No abstract available.
Acute Kidney Injury*
7.L-carnitine in maintenance hemodialysis clinical, lipid and biochemical effects.
Hee Jeong SOHN ; Gyu Bog CHOI ; Kyun Ill YOON
Korean Journal of Nephrology 1992;11(3):260-269
No abstract available.
Carnitine*
;
Renal Dialysis*
8.Anticardiolipin Antibody (ACA) and Lupus Anticoagulant (LA): Association with Vascular Access Occlusion in Hemodialysis (HD) Patients.
Duk Hee KANG ; Seung Ki RYU ; Sung Nam KIM ; Kyun Il YOON ; Yoon Ha LEE
Korean Journal of Medicine 1997;53(5):661-670
OBJECTIVES: Anticardiolipin antibody (ACA) and lupus anticoagulant (LA) are acquired antiphospholipid antibodies (APAs), which are regarded as important risk factors far vascular thrombosis and recurrent fetal loss. Although the clinical relevance of APAs in dialysis patients is uncertain, recent studies have suggested that APAs are involved in bioincompatibility and thrombogenic complications in hemadialysis (HD) patients. METHOD: We performed a cross sectional study of ACA and LA in 50 stable HD patients and their 68 vascular accesses (52 native arteriovenous fistulae and 16 synthetic arterovenous grafts), with the analysis of factors associated with the presence of APAs and the retrospective evaluation of vascular access occlusion (VAO). LA was assessed by platelet neutralization method whereas IgG-ACA was measured by a solid phase ELISA. Values higher than 23GPLU/ml (IgG phospholipid units) were considered to be positive for IgG-ACA and positive values for LA was more than 8 seconds in prolongation of the clotting time with human platelet lysate. Vascular access survival was assessed by Kaplan- Meier method, RESULTS: The mean age of the subject (M:F 21:29) was 46 years and the mean duration of hemodialysis was 49 months. The frequency of VAO in entire subjects was 0.45+/-0.98 episodes/patient year. The median value of IgG-ACA was 16.0 GPLU/ml with a distribution from 2.7 to 46.1GPLU/ ml. The median titer of I.A was 4.5 (3.1-45.6) seconds. Fourteen patients (28%) were found to have at least one episode of VAO. In spite of comparable clinical and biochemical data according to the presence of VAO, the titers of IgG-ACA (13.6+/-7.7 vs, 20.3+/-8.7GPLIJ/ml, P<0.05) and LA (4.5+/-2.9 vs. 11.7 +/-12.6sec, P<0.05) were significantly higher in VAO group. Six out of 50 patients(12%) had an increased titer of IgG-ACA and LA was found in 11 patients(22%). No patients were positive for ACA and LA simultaneously. There was no significant difference in sex, etiology of ESRD, diabetic status, the dosage of heparin during HD or the amount of erythropoietin administered according to the presence of APAs. We could not find any significant correlation between the titer of APAs and age, duration of dialysis, blood pressure, platelet count and biochemical parameters. In the patients with positive ACA, the frequency of VAO was 1.05+/-0.12 episodes/patient year, which was significantly higher than patients without ACA (0.33+/-0.17 episodes/ patient year, P<0.05). In the patients with the presence of LA(1.06+/-0.43 vs. 0.12+/-0.06 episodes/ patients year, P<0.01). The median vascular access survival time in IgG-ACA positive patients (32.7 months) was significantly decreased compared to 66.8 months in IgG-ACA negative group. CONCLUSION: Our data suggest that the presence of APAs (ACA and/or LA) affects the event-free vascular access survival in HD patients. Therefore the evaluation of APAs status have to be included in the diagnostic strategies for the patients with recurrent VAO. Further studies are necessary to explore the pharmacologic intervention method to decrease APAs and prevent VAO in HD patients.
Antibodies, Anticardiolipin*
;
Antibodies, Antiphospholipid
;
Arteriovenous Fistula
;
Blood Platelets
;
Blood Pressure
;
Dialysis
;
Enzyme-Linked Immunosorbent Assay
;
Erythropoietin
;
Heparin
;
Humans
;
Kidney Failure, Chronic
;
Lupus Coagulation Inhibitor*
;
Platelet Count
;
Renal Dialysis*
;
Retrospective Studies
;
Risk Factors
;
Thrombosis
9.Congenital tuberculosis
Seong Ku WOO ; Young Kyun YOON ; Yup YOON ; Cheol Min PARK ; Soon Yong KIM
Journal of the Korean Radiological Society 1984;20(3):519-524
Congenital tuberculosis is an infection that is established in the fetus by hematogenous spread or by the aspiration or inhalation of infected amniotic fluid either before or during labor. The diagnosis can be confirmed only if both the tuberculous nature of the lesion and the antenatal origin of the infection can be proved. The authors analysed roentgen findings of two cases of pulmonary tuberculosis, thought to be congenital; 1. Diffuse distribution of nodular densities and some confluent densities were seen in the entire lungs in the inital film.The pulmonary markings were decreased in some degree. 2. Air bronchogram was noted. 3. Hepatosplenomegaly was associated.
Amniotic Fluid
;
Diagnosis
;
Female
;
Fetus
;
Inhalation
;
Lung
;
Tuberculosis
;
Tuberculosis, Pulmonary
10.Plasma Glucose and Insulin Changes during IV Theophyline Therepy in Preterm Infants with Apnea.
Young Wook YOON ; Yeon Kyun OH ; Eun Hee LEE ; Jung Youl SONG
Korean Journal of Perinatology 1998;9(1):26-30
PURPOSE: The purpose of this study was to evaluate the effects of theophylline in preterm infants with apnea on glucose homeostasis and insulin values. METHOD: In this prospective study, level of glucose and insulin were measured from peripheral blood of 8 neonates(1,450+/-114gm, 31+/-2.1week), who were admitted from April 1, 1997 to July 30, 1997 in Neonatal Intensive Care Unit of Wonkwang University Hospital, for apnea of prematurity(> 20 sec with bradycardia and/or cyanosis) were given aminophylline intravenously. Blood samples were collected at pretreatment, posttreatment 2hours, 1-2days, 3-4days, 5-7days and posttreatment 48hours, and compare to those of the 8 control neonates(1,711+/-232gm, 32+/-1.7week). RESULTS: The results were as follows: 1) Plasma glucose values were significantly higher in the treatment group than those of the control group at 1-2days(104.67+/-20.39mg/dL vs 83.43+/-15.86mg/dL) and 3-4days(111.0+/-32.39mg/dL vs 79.25+/-14.03mg/dL)(p<0.05). 2) Plasma glucose values which were increased at 1-2days(104.67+/-20.39mg/dL)and 3-4days(111.0+-32.39mg/dL), were significantly higher than pretreatment values(66.33+/-31.19mg/ dL)(p<0.02), but were not increased to the level of hyperglycemia(> 125mg/dL). 3) The mean posttreatment glucose levels drawn at 48hours after discontinuation of theophylline was significantly decreased to the values of pretreatment values compared to those of the 1-2days and 3-4days(p<0.01). 4) Insulin concentrations were also increased insignificantly when blood glucose were increased in the treatment group compared with control group. CONCLUSION: In conclusion, intravenous administration of theophylline produces hyperglycemia significantly, including an increase in a serum insulin. But, clinically significant hyperglycemia(> 125mg/dL) was not noted. So, plasma glucose may not need to be monitored in preterm apneic infants receiving theophylline. But, further studies are need to elucidate the effect of theophylline considering the serum toxic level of theophylline.
Administration, Intravenous
;
Aminophylline
;
Apnea*
;
Blood Glucose*
;
Bradycardia
;
Glucose
;
Homeostasis
;
Humans
;
Hyperglycemia
;
Infant
;
Infant, Newborn
;
Infant, Premature*
;
Insulin*
;
Intensive Care, Neonatal
;
Plasma*
;
Prospective Studies
;
Theophylline